KR20150082811A - Food composition for preventing senile dimentia comprising Dendropanax morbifera Lev. extract - Google Patents
Food composition for preventing senile dimentia comprising Dendropanax morbifera Lev. extract Download PDFInfo
- Publication number
- KR20150082811A KR20150082811A KR1020140002226A KR20140002226A KR20150082811A KR 20150082811 A KR20150082811 A KR 20150082811A KR 1020140002226 A KR1020140002226 A KR 1020140002226A KR 20140002226 A KR20140002226 A KR 20140002226A KR 20150082811 A KR20150082811 A KR 20150082811A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- food composition
- present
- extracts
- dendropanax morbifera
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 73
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 235000013305 food Nutrition 0.000 title claims abstract description 25
- 241000392544 Dendropanax morbifer Species 0.000 title abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
- 230000002265 prevention Effects 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 5
- 230000008020 evaporation Effects 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 240000006439 Aspergillus oryzae Species 0.000 claims description 3
- 235000002247 Aspergillus oryzae Nutrition 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 19
- 235000013376 functional food Nutrition 0.000 abstract description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 6
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 5
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 201000005577 familial hyperlipidemia Diseases 0.000 description 10
- 230000036541 health Effects 0.000 description 9
- 108010007622 LDL Lipoproteins Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- DVDUMIQZEUTAGK-UHFFFAOYSA-N p-nitrophenyl butyrate Chemical compound CCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 DVDUMIQZEUTAGK-UHFFFAOYSA-N 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 108010010234 HDL Lipoproteins Proteins 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 241000282326 Felis catus Species 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- UYXTWWCETRIEDR-UHFFFAOYSA-N Tributyrin Chemical compound CCCC(=O)OCC(OC(=O)CCC)COC(=O)CCC UYXTWWCETRIEDR-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 3
- KBMBZBANUJGWRA-UHFFFAOYSA-N C(CCCCCCCCCCCCCCC)(=O)OC1OC=CC(=C1)[N+](=O)[O-] Chemical compound C(CCCCCCCCCCCCCCC)(=O)OC1OC=CC(=C1)[N+](=O)[O-] KBMBZBANUJGWRA-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 241001518926 Cladrastis Species 0.000 description 3
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 3
- 108010069201 VLDL Cholesterol Proteins 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 235000007063 yellowwood Nutrition 0.000 description 3
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000002789 Panax ginseng Nutrition 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 239000004922 lacquer Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002366 lipolytic effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- LVZSQWIWCANHPF-UHFFFAOYSA-N p-nitrophenyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LVZSQWIWCANHPF-UHFFFAOYSA-N 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000190633 Cordyceps Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000202573 Dendropanax Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 239000006000 Garlic extract Substances 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- TXKMVPPZCYKFAC-UHFFFAOYSA-N disulfur monoxide Inorganic materials O=S=S TXKMVPPZCYKFAC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000006253 efflorescence Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000020706 garlic extract Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940065115 grapefruit extract Drugs 0.000 description 1
- 229940107702 grapefruit seed extract Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical compound S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
- A23L3/44—Freeze-drying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Botany (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 황칠 추출물을 포함하는 노인성 질환 예방용 식품 조성물에 관한 것으로, 더욱 구체적으로는 황칠추출물을 포함하는 노인성 질환, 예를 들면 고지혈증, 알쯔하이머 질환의 예방용 식품 조성물 및 그의 제조 방법에 관한 것이다.More particularly, the present invention relates to a food composition for preventing senile diseases, for example, hyperlipemia and Alzheimer's disease, and a method for producing the composition.
현대인의 사망률은 고지혈증, 혈전증, 고혈압, 심혈관 질환 등이 주된 원인이 되고 있으며, 이러한 질병에 의한 사망률은 매년 급증하고 있으며, 이러한 질환은 세계 의약품시장 중 심혈관질환 기표제의 시장규모가 약효군 별로 볼 때 제 1위(약 21%)를 점유하고 있다.The mortality rate of modern people is mainly caused by hyperlipemia, thrombosis, hypertension, cardiovascular disease, etc. The mortality due to these diseases is rapidly increasing every year, and the market of cardiovascular disease markers among the world market It occupies the first place (about 21%).
우리나라는 세계에서 가장 빠르게 인구 고령화가 진행되고 있는 국가 중의 하나가 되었고, 2018년 고령사회(65세 이상 인구가 전체인구의 14% 이상)에 진입을 눈앞에 두고 있으며, 2026년에는 초고령사회(65세 이상 인구가 전체인구의 20% 이상)로의 변화가 예상되고 있다.Korea is one of the fastest growing aging countries in the world. In 2018, an aged society (over 65 years old is more than 14% of the total population) is in the forefront. In 2026, The population aged 65 and over is expected to be more than 20% of the total population).
통계에 의하면 65세 이상 노인 100명 중 8~9명이 치매 환자이며, 2000년도에 25만명 정도였으나 2011년 말 기준 50만 명으로 12년 사이에 치매 환자가 두 배 증가하였다.According to statistics, 8 to 9 out of 100 elderly people aged 65 or older are dementia patients, and in 2000, it was about 250,000, but as of the end of 2011, it was 500,000 and the number of dementia patients doubled in 12 years.
한편, 21세기 생명공학의 발달, 건강에 대한 욕구 증대 등으로 식품에 대한 건강과 안정성 지향이 급속히 강조되면서 식품에 대한 인식이 점점 바뀌고 있다.On the other hand, as the development of biotechnology in the 21st century and the increase in desire for health, the awareness of food is gradually changing as the emphasis on health and stability of food is rapidly emphasized.
건강기능식품은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조, 가공한 식품으로 정의하고 있는데 건강기능식품은 의약품과 달리 질병상태의 치료가 목적이 아니라 생체기능의 활성화를 통해 질병 발생 위험을 감소시키거나 건강유지, 증진을 목적으로 하고 있다.Health functional foods are defined as foods manufactured and processed using raw materials or ingredients with useful functions in the human body. Unlike pharmaceuticals, health functional foods are not intended for the treatment of disease conditions, And to maintain or improve health.
우리나라에서는 1990년대 후반부터 기능성 식품에 대한 관심을 가지지 시작하였고, 최근 소득증가와 소비수준의 향상으로 건강에 대한 관심이 증가하면서 건강식품에 대하여도 선호도가 높아지고 있다.In Korea, since the late 1990s, interest in functional foods has begun to emerge. Recently, as interest in health has increased due to an increase in income and an increase in consumption level, preference for health foods has also increased.
또한 각종 자료에서 향후 고령 인구의 삶의 질에 대한 요구가 단순 수명 연장에서 건강 수명의 증가로 변화하고 있음을 보여주고 있다. 특히, 심혈관질환과 더불어 산업화로 인한 환경 오염물질의 증가, 스트레스, 노령인구의 증가 등은 이러한 건강 수명에 대한 중요한 화두이다.In addition, various data show that the demand for quality of life of the elderly population is changing from simple life extension to health life extension. In particular, the increase in environmental pollutants due to industrialization along with cardiovascular disease, stress, and an increase in the elderly population are important topics for health life.
현재 완치보다는 증상을 호전시키기 위해 많은 약물이 사용되고 있지만 사용 범위와 시기의 제한성, 부작용 등으로 천연물을 이용하여 이를 예방하고 치료하기 위한 기능성 식품 개발에 대한 요구가 높아지고 있다.Currently, many drugs are used to improve symptoms rather than cure. However, there is a growing demand for the development of functional foods for preventing and treating natural substances due to limited range of use, timing, and side effects.
또한, 농촌에서는 현재 농산물의 수입개방으로 인하여 농가에서는 적당한 유망작목 선택에 어려움을 겪고 있으며 생물다양성 협약에 의해 유전 자원의 중요성이 그 어느 때보다 크게 인식되고 있다.In rural areas, farmers are having difficulties in choosing suitable prospective crops due to the opening of agricultural imports, and the importance of genetic resources is recognized more than ever by the Convention on Biological Diversity.
따라서, 직접 혈전에 작용하고 부작용을 최소화시킬 수 있으며 저렴한 가격의 혈전분해제를 개발할 필요성이 대두되고 있다. Therefore, there is a need to develop an inexpensive thrombolytic agent which can act directly on thrombus and minimize side effects.
본 발명자들은 천연물을 대상으로 기능성 물질을 탐색하여 개발하기 위하여 예의 연구한 결과, 황칠나무의 추출물이 노인성 질환의 예방에 적합할 뿐만 아니라 부작용이 없음을 발견하고 이것이 노인성 질환의 예방을 위한 건강 식품으로서 효율적으로 활용될 수 있음을 발견하고 본 발명을 완성하기에 이르렀다.The inventors of the present invention have made intensive studies to search for and develop functional materials on natural products. As a result, they found that the extract of Hwangchu-myeon is not only suitable for prevention of geriatric diseases but also has no side effects, and this is a health food for prevention of geriatric diseases And the present invention has been accomplished.
따라서, 본 발명의 목적은 황칠나무 추출물을 유효 성분으로 포함하는 것을 특징으로 하는 노인성 질환의 예방용 식품 조성물을 제공하는 데에 있다.Accordingly, an object of the present invention is to provide a food composition for the prevention of geriatric diseases, which comprises an extract of Aspergillus oryzae as an active ingredient.
본 발명의 목적은, 추가의 일면에 있어서, 상기 황칠나무 추출물은 The object of the present invention is, in a further aspect,
황칠나무를 세척한 후, 60~90% 메탄올에 침지시킨 후 3일 내지 15일 동안 실온에서 방치한 후 추출액만 분리하고, 얻은 추출액을 증발하여 농축시킨 후 동결건조하여 분말상태로 제조하거나,After washing the woodwort, it is immersed in 60 to 90% methanol, and then left at room temperature for 3 to 15 days. Only the extract is separated, and the obtained extract is evaporated to concentrate and freeze-
채취한 황칠나무를 깨끗이 세척하고 건조하여 세절한 후, 에탄올 60~90%에 침지시킨 후, 실온에서 1~3 주 동안 방치한 후 추출액을 분리하고, 얻은 추출액을 증발하여 농축시킨 후 동결건조하여 분말상태로 제조하거나, 또는 The extracts were separated by evaporation, and the extracts were evaporated to dryness, and the extracts were lyophilized. After drying, the extracts were washed three times and then immersed in 60 to 90% ethanol. Or in powder form, or
황칠나무를 깨끗이 세척하여 건조하여 세절한 다음 이를 용기에 넣고 황칠나무와 물을 중량을 기준으로 1:1~5중량부로 혼합하여 고압멸균솥에 넣고 95 ~ 125℃의 온도에서 2 ~ 5 시간 동안 추출하여 여과하여 농축하여 얻어진 것을 특징으로 하는 노인성 질환 예방용 식품 조성물을 제공하는 데에 있다.It is mixed with 1: 1 ~ 5 parts by weight of Hwangjak tree and water, put into a high pressure autoclave and heated at 95 ~ 125 ℃ for 2 ~ 5 hours Extracting, filtering and concentrating the composition. The present invention also provides a food composition for the prevention of geriatric diseases.
이상 살펴본 바와 같이, 본 발명에 따른 황칠나무 추출물은 고지혈증 등의 노인성 질환의 예방에 효능이 있음을 확인할 수 있다. 따라서, 본 발명에 따른 황칠나무 추출물은 노인성 질환의 예방을 위한 식품으로 효과적으로 이용될 수 있다. 뿐만 아니라 지역 참여기업에 의한 노인 복합 질환 맞춤형 기능성 식품 소재의 대량생산기술 개발에 의한 지역소득원 및 생물산업에 대한 전문인력의 고용 창출 효과가 있다.As described above, it can be confirmed that the extract of Wuchulia chinense according to the present invention is effective for the prevention of geriatric diseases such as hyperlipemia. Therefore, the extract of Wuchulia chinense according to the present invention can be effectively used as a food for the prevention of geriatric diseases. In addition, it has the effect of creating employment of local labor sources and biotechnology industry by mass production technology of functional food ingredients tailored for the elderly by local participating companies.
도 1은 황칠 추출물의 마우스 혈액 클롯 분해 분석의 결과도.
도 2는 황칠 추출물의 TBA 플레이트 에세이의 결과도.
도 3은 고지혈증 유발 쥐에서 황칠 추출물의 항고지혈 효과를 나타내는 그라프도이다.1 is a result of analysis of mouse blood clot analysis of Huangchil extract.
Figure 2 is a result of TBA plate assay of Huangchil extract.
FIG. 3 is a graph showing the antihyperlipidemic effect of Huangchil extract in hyperlipemia-induced rats.
본 발명은, 일면에 있어서, 황칠나무 추출물을 유효 성분으로 포함하는 것을 특징으로 하는 노인성 질환의 예방용 식품 조성물을 제공한다.The present invention provides, in one aspect, a food composition for the prevention of geriatric diseases, which comprises an extract of Aspergillus oryzae as an active ingredient.
본 발명은, 추가의 일면에 있어서, 상기 황칠나무 추출물은 In a further aspect of the present invention,
황칠나무를 세척한 후, 60~90% 메탄올에 침지시킨 후 3일 내지 15일 동안 실온에서 방치한 후 추출액만 분리하고, 얻은 추출액을 증발하여 농축시킨 후 동결건조하여 분말상태로 제조하거나,After washing the woodwort, it is immersed in 60 to 90% methanol, and then left at room temperature for 3 to 15 days. Only the extract is separated, and the obtained extract is evaporated to concentrate and freeze-
채취한 황칠나무를 깨끗이 세척하고 건조하여 세절한 후, 에탄올 60~90%에 침지시킨 후, 실온에서 1~3 주 동안 방치한 후 추출액을 분리하고, 얻은 추출액을 증발하여 농축시킨 후 동결건조하여 분말상태로 제조하거나, 또는The extracts were separated by evaporation, and the extracts were evaporated to dryness, and the extracts were lyophilized. After drying, the extracts were washed three times and then immersed in 60 to 90% ethanol. Or in powder form, or
황칠나무를 깨끗이 세척하여 건조하여 세절한 다음 이를 용기에 넣고 황칠나무와 물을 중량을 기준으로 1:1~5중량부로 혼합하여 고압멸균솥에 넣고 95 ~ 125℃의 온도에서 2 ~ 5 시간 동안 추출하여 여과하여 농축하여 얻어진 것을 특징으로 하는 노인성 질환 예방용 식품 조성물을 제공한다.It is mixed with 1: 1 ~ 5 parts by weight of Hwangjak tree and water, put into a high pressure autoclave and heated at 95 ~ 125 ℃ for 2 ~ 5 hours Extracting, filtering and concentrating the composition. The present invention also provides a food composition for the prevention of geriatric diseases.
황칠나무는 그 학명이 Dendropanax morbifera Lev.로서 우리나라에서만 자생하는 천연보호림이며, 두릅나무과에 속하는 상록활엽교목으로 겨울에도 낙엽이 지지 않으며, 세계적으로도 귀한 난지성 수목으로, 우리나라에는 1속 1종 밖에 없으며 서남해안 및 제주도, 진도, 장흥, 완도, 해남, 거제도 등 도서지역에 자생하고, 특히 전라남도가 전국 재배량의 99%를 차지하고 있으며, 10년생 이상의 수목들이 대량 재배되고 있는 상록활엽교목으로 예전부터 다양한 용도로 사용되어 왔으며, 수피에 상처를 주면 수지액이 흘러나오는데 이러한 수지액을 황칠이라 부른다. 그 樹皮에서 나오는 黃漆은 찬란한 금빛을 띄어서 예전부터 황칠은 황제의 갑옷, 금속 장신구 등의 외간을 황금색으로 장식하는 진귀한 도료로 사용되어 왔으며, 안식향을 함유하여 예로부터 약리효과가 탁월한 신비한 나무로 주목을 받아 왔다. Dendropanax is a plant of the genus Dendropanax morbifera Lev. It is a natural protected forest that is native to Korea only. It is an evergreen broad-leaved arboreous tree belonging to Araliaceae. It is a deciduous tree in winter, , Jangheung, Wando, Haenam, and Geoje Island. Jeollanam-do occupies 99% of the whole country's cultivated area. It is an evergreen broad-leaved arboreous tree that has been cultivated for over 10 years. If a scratch is given to the resin liquid, the resin liquid is referred to as "sulfur oxide". Huang Lacquer from the bark has a brilliant golden color, and Huangchil has been used as a rare paint to decorate the exterior of the emperor's armor, metal ornaments, etc. with golden color. It is noted as a mysterious tree with excellent antimicrobial effect .
황칠나무는 인간의 질병의 치유 및 예방에 유용한 성분을 다량 함유하고 있고, 최근 들어 다양한 기능성 연구결과가 보고되고 있어 전문적인 제품화기술 및 마케팅 지원을 통하여 충분히 건강기능식품 및 웰빙식품으로 고부가가치화 제품을 개발 할 수 있고 지역경제 활성화에 큰 영향을 줄 수 있을 것으로 판단된다.Hwangchujak contains a large amount of ingredients useful for the healing and prevention of human diseases. Recently, various functional research results have been reported. Through the help of professional producting technology and marketing support, we can provide high value-added products as health functional foods and well- And can greatly affect the regional economy.
따라서, 본 발명은 이러한 황칠나무의 유익한 성분을 노인성 질환의 예방용 식품 조성물로서 개발하기 위하여 예의 노력한 결과 이루어진 것이다.Accordingly, the present invention has been made with intensive efforts to develop such a beneficial component of Hwangchujang as a food composition for the prevention of geriatric diseases.
황칠나무 추출액을 얻기 위한 방법으로는 황칠나무를 세척한 후, 60~90% 메탄올에 침지시킨 후 3일 내지 15일 동안 실온에서 방치한 후 추출액만 분리하고, 얻은 추출액을 증발하여 농축시킨 후 동결건조하여 분말상태로 제조하거나,As a method for obtaining the extract of Hwangchujang, the Hwangchujang was washed, immersed in 60 ~ 90% methanol, left for 3 ~ 15 days at room temperature, only the extract was separated, and the obtained extract was evaporated, Dried to produce a powder,
채취한 황칠나무를 깨끗이 세척하고 건조하여 세절한 후, 에탄올 60~90%에 침지시킨 후, 실온에서 1~3 주 동안 방치한 후 추출액을 분리하고, 얻은 추출액을 증발하여 농축시킨 후 동결건조하여 분말상태로 제조하거나, 또는The extracts were separated by evaporation, and the extracts were evaporated to dryness, and the extracts were lyophilized. After drying, the extracts were washed three times and then immersed in 60 to 90% ethanol. Or in powder form, or
황칠나무를 깨끗이 세척하여 건조하여 세절한 다음 이를 용기에 넣고 황칠나무와 물을 중량을 기준으로 1:1~5중량부로 혼합하여 고압멸균솥에 넣고 95 ~ 125℃의 온도에서 2 ~ 5 시간 동안 추출하여 여과하여 농축하여 얻는다.It is mixed with 1: 1 ~ 5 parts by weight of Hwangjak tree and water, put into a high pressure autoclave and heated at 95 ~ 125 ℃ for 2 ~ 5 hours Extraction, filtration and concentration.
본 발명에 따른 황칠나무 추출물은 천연 식물추출물로서 무독성이고, 항고지혈증 효과를 나타내므로 고지혈증, 파킨슨 병 등의 예방을 위한 식품으로서 사용할 수 있다.According to the present invention, the extract is a natural plant extract which is non-toxic and exhibits an antihyperlipidemic effect, and thus can be used as a food for preventing hyperlipidemia, Parkinson's disease and the like.
따라서, 본 발명은, 추가의 일면에 있어서, 유효 성분으로서 상기 황칠나무 추출물을 포함하는 노인성 질환의 예방용 식품 조성물을 제공한다. Accordingly, the present invention provides, in a further aspect thereof, a food composition for the prevention of an geriatric disease comprising the extract of Hokkaido, as an active ingredient.
본 발명의 노인성 질환의 예방을 위한 식품을 적용할 수 있는 질환으로는, 이들에 한정되지 않고, 고지혈증, 알쯔하이머 질환 등을 포함할 수 있으며, 본 발명의 조성물은 상기 질환에 특히 바람직하게 사용될 수 있으며, 당업자는 그러한 질병, 상태 및 이상으로부터 고통을 받는 것으로 추정되는 개인들을 용이하게 파악할 수 있다. The diseases to which the food for the prevention of the geriatric disease of the present invention can be applied include, but are not limited to, hyperlipidemia, Alzheimer's disease and the like. The composition of the present invention can be particularly preferably used for the diseases , Those skilled in the art will readily be able to identify individuals who are suspected of suffering from such diseases, conditions and disorders.
본 발명에 따른 식품 조성물의 제형은, 당해 분야에서의 통상적인 방법에 따라, 예를 들면 경구제, 환제, 파우치제, 또는 드링크제 등의 음료수의 형태로 제형화시켜 사용할 수 있다.The formulations of the food composition according to the present invention can be formulated in the form of beverages such as oral preparations, pills, pouches, or drinks according to the conventional methods in the art.
특히, 환제로 제조하는 경우에는 각 재료를 더블콘 혼합기 등의 혼합기에서 20분 이상 혼합한 후, 연합기를 사용하여 연합하고, 통상의 제환기를 이용하여 제환한 후 약 30℃ 전후에서 건조하고, 이를 코팅하고 포장하여 제조할 수 있다.Particularly, in the case of manufacturing with a pellet, the respective materials are mixed in a mixer such as a double cone mixer for 20 minutes or more, and then combined using a coater. The mixture is cooled using a conventional ventilator, dried at about 30 캜, Which can be prepared by coating and packaging.
또한 코팅시에는 히드록시프로필메틸셀룰로오스를 95% 주정에 용해한 후 스프레이 방식으로 코팅하는 것이 바람직할 수 있고, 건조기상에서 30 ± 2℃에서 1 시간 이상 수분 함량 5%이하로 건조하여 포장하는 것이 좋다.For coating, it may be preferable to dissolve hydroxypropylmethylcellulose in a 95% alcohol solution followed by spray coating. It is preferable to dry and coat the product at a temperature of 30 ± 2 ° C for at least 1 hour to a water content of 5% or less.
본 발명의 식품 조성물의 복용량은, 그 제제 형태, 투여 방법, 사용 목적 및 이것에 적용되는 개인의 연령, 체중, 증상에 따라서 적절히 설정되고, 일정하지 않지만 일반적으로는 제제 중에 함유되는 유효성분의 양은 1캡슐 450mg 당 20mg∼100mg으로 성인 기준으로 1일 6캡슐 복용량으로 할 수 있다. 물론 복용량은, 각종 조건에 의해서 변동하기 때문에, 상기 범위 보다 적은 양으로 충분한 경우도 있고, 또는 범위를 초과하여 필요한 경우도 있다.The dosage of the food composition of the present invention is appropriately set in accordance with the form of the composition, the method of administration, the purpose of use, and the age, weight and symptom of the individual to which the composition is applied. Capsules from 20mg to 100mg per 450mg can be taken as an adult dose of 6 capsules per day. Of course, since the dosage varies depending on various conditions, the amount may be less than the above range, or may be more than the above range.
본 발명에 따른 식품 조성물은 원하는 조성물의 형태에 따라 통상의 보조제 또는 첨가제, 또는 감미료, 예를 들면 벌꿀, 맥아, 글리세린, 홍삼, 산수유, 복령, 숙지황, 가시오가피, 동충하초, 자몽 추출물, 감초, 맥류약엽분말, 서양산사자추출물, 세인트존스워트, 셀레늄효모, 비타민 C, 구연산, 니코틴산, 안식향산나트륨, 아스파탐, 사카린, 펙틴, 말리톨, 솔비톨, 자일리톨, 구아검, 탈지분유 및 올리고당으로 이루어진 군 중에서 선택되는 하나 이상의 성분을 추가하여 기호도나 미감을 증대시킬 수 있다. 이들은 본 발명의 조성물의 전체 중량을 기준으로 약 50∼80% 로 사용하는 것이 적절하다.
The food composition according to the present invention may contain conventional additives or additives, or sweeteners such as honey, malt, glycerin, red ginseng, corn syrup, gyeongryeo, sorghum, garlic extract, cordyceps, grapefruit extract, licorice, One selected from the group consisting of lactose, sucrose, powder, xanthan extract, St. John's wort, selenium yeast, vitamin C, citric acid, nicotinic acid, sodium benzoate, aspartame, saccharin, pectin, maltitol, sorbitol, xylitol, guar gum, The above components can be added to increase taste and aesthetics. They are suitably used in an amount of about 50 to 80% based on the total weight of the composition of the present invention.
<실시예><Examples>
이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
실시예 1: 황칠나무의 잎 추출물의 제조Example 1: Preparation of Leaf Extract of Yellowwood
황칠나무의 건조된 잎 3 kg을 70% 메탄올 3 ℓ에 침지하여 1주일 동안 실온에서 방치한 후 추출액만 분리하였다. 얻은 추출액을 증발하여 농축시킨 후 동결건조하여 분말상태로 황칠추출물 135 g을 제조하였다.
3 kg of dried leaves of Hwangchu - wood were immersed in 3 ℓ of 70% methanol and left at room temperature for 1 week. The obtained extract was concentrated by evaporation and then lyophilized to obtain 135 g of Huangchil extract powder.
실시예 2: 황칠나무의 잎 추출물의 제조Example 2: Preparation of Leaf Extract of Yellowwood
채취한 황칠나무의 잎을 세척 후 건조하여 3kg을 세절한 후, 90% 에탄올 5 리터에 넣고 실온에서 2 주 동안 침출시키고 이를 여과하고, 이 과정을 반복하여 여액을 합한 후 농축시켜 황칠나무 추출물 135g을 분말로 얻었다.
The leaves were washed and dried, and 3 kg of the leaves were removed. The leaves were added to 5 liters of 90% ethanol, and the leaves were leached at room temperature for 2 weeks. The leaves were filtered and the filtration was repeated. The filtrates were combined and concentrated to obtain 135 g As a powder.
실시예 3: 황칠나무의 잎 추출물의 제조Example 3: Preparation of Leaf Extract of Yellowwood
황칠나무의 잎을 깨끗이 세척하여 건조하여 세절한 다음 주정과 1:1~5의 비율로 배합하여 25~ 30℃의 온도에서 일주일 동안 침출시켜 황칠나무 추출액을 얻었다.
The leaves were washed thoroughly, dried and blended in a ratio of 1: 1 ~ 5, and leached at 25 ~ 30 ℃ for 1 week.
실시예Example 4: 건강식품 제제 4: Health food preparation
제형의 형태(정제) Form of formulation (tablets)
황칠나무 추출물(실시예 1) 10 mg10 g (Example 1)
락토오스
60 mg
전분 15 mgStarch 15 mg
스테아르산 마그네슘 5 mgMagnesium stearate 5 mg
결정성 셀룰로오스
15 mg
Crystalline cellulose 15 mg
본 발명의 한 실시 형태는 그 예를 상기에 나타낸 정제의 유효 성분으로써 상기 건강 식품의 용도이다. 정제는 통상의 방법에 의해 제조될 수 있으며, 한 바람직한 실시형태는 통상의 장용성 피복(예를 들면, 히드록시프로필메틸 셀룰로오스 프탈레이트), 당코팅 또는 피막 코팅을 갖는 정제 또는 연질캅셀 형태이다.
One embodiment of the present invention is the use of the above-mentioned health food as an example of an effective ingredient of the tablet as described above. Tablets may be prepared by conventional methods and one preferred embodiment is in the form of tablets or soft capsules with conventional enteric coatings (e. G., Hydroxypropylmethylcellulose phthalate), sugar coating or coatings.
실시예Example 5: 5: 환제Pill 제조 Produce
실시예 1의 황칠 추출분말 5%(이하, 중량기준), 꿀 31%, 맥아분말 14.95%, 글리세린 11%, 홍삼분말 10%, 산수유분말 7%, 복령분말 7%, 가시오가피분말 7%, 숙지황농축액 5%, 동충하초분말 2% 및 자몽종자추출물 0.05%을 더블콘 혼합기에서 25분 동안 혼합한 후, 연합기를 사용하여 연합하고, 제환기를 이용하여 제환한 후 약 30℃ 전후에서 건조하고, 히드록시프로필메틸셀룰로오스를 95% 주정에 용해한 후 스프레이 방식으로 코팅하고, 건조기 상에서 30 ± 2℃에서 1 시간 동안 수분 함량 5% 이하로 건조하여 포장(PS)하여 내용량이 3.5g인 환제를 제조하였다.
5% (by weight) of honey extract, 31% of malt powder, 14.95% of malt powder, 11% of glycerin, 10% of red ginseng powder, 7% of cornstarch powder, 7% of ginseng powder, 7% of ginseng powder, 5% of concentrate, 2% of Cordycepsis powder and 0.05% of grapefruit seed extract were mixed in a double cone mixer for 25 minutes and then combined using a coater. The mixture was air-conditioned and dried at about 30 캜, Hydroxypropylmethylcellulose was dissolved in 95% alcohol, spray coated, and dried at 30 ± 2 ° C for 1 hour to a moisture content of 5% or less and packed (PS) to prepare a pellet having an amount of 3.5 g.
실시예Example 6: 음료수의 제조 6: Manufacture of drinking water
실시예 1에서 얻은 황칠추출물 100 g에 구연산 20g, 아스파탐 17 g 및 비타민 C 30 g을 첨가한 후 나머지를 정제수로 첨가하여 음료수 10 ℓ를 제조하여 저온 살균하였다. 결과적으로 본 발명 음료수는 종래의 음료수 제품과 입안 감촉, 맛 그리고 종합평가 면에서 양호한 반응을 얻었다.
20 g of citric acid, 17 g of aspartame and 30 g of vitamin C were added to 100 g of the Huangchil extract obtained in Example 1, and the remaining was added with purified water to make 10 L of drinking water and pasteurized. As a result, the beverage of the present invention obtained favorable responses to conventional beverage products in terms of mouth feel, taste, and overall evaluation.
실시예Example 7: 단백질 정량 7: Quantification of protein
실시예 1에 따른 황칠추출물의 단백질 정량은 공지된 Lowry 등의 방법에 의한 BCA 단백질정량 kit (Pierce Co., USA)를 사용하여 측정하였으며, 표준 단백질은 bovine serum albumin (BSA)을 사용하였다. 에탄올을 이용한 황칠 추출물은 1.108㎍/㎕ 의 protein density를 보였다.
Protein quantification of the Huangchil extract according to Example 1 was performed using a BCA protein quantification kit (Pierce Co., USA) by the well-known method of Lowry et al., And bovine serum albumin (BSA) was used as a standard protein. The extract of Huangchil using ethanol showed a protein density of 1.108 ㎍ / ㎕.
실시예Example 8: 급성 독성 시험 8: Acute toxicity test
실시예 1에 따른 황칠추출물의 실험동물에 대한 독성 실험을 수행하고 그 독성유무를 관찰하였다. 실험용동물은 4, 5주령의 체중 105±4g의 수컷과 95±3g의 암컷의 SD계 래트 60 마리를 사용하였고 본 발명의 추출물과 음성대조군으로서 증류수를 사용하여 시험하였다. 먼저, 상기 래트들을 온도 22±2℃, 상대습도 53±2% 및 형광등 조명(09:00 점등-18:00 소등)의 명암사이클, 150-300 Lux의 조도 조건을 갖춘 실험실 사육 상자에서 약 1주일 정도의 기간에 걸쳐 순화시킨 다음, 건강한 동물들만을 선택하여 평균 체중이 일치하도록 각 군으로 나누고 일일 1회 20ml/kg의 양으로 14일 동안 강제 경구투여한 다음, 일반상태의 변화, 중독증상, 운동성, 외관, 자율신경, 체중변화 및 사망동물의 유무에 관하여 점검하였다.Toxicity test of the Huangchil extract according to Example 1 was performed and its toxicity was observed. Male and female SD male rats weighing 105 ± 4 g and male and female weighing 95 ± 3 g were used as test animals. The extracts of the present invention were tested using distilled water as a negative control. First, the rats were incubated in a laboratory incubation box with a light and dark cycle of temperature 22 ± 2 ° C., relative humidity 53 ± 2% and fluorescent light (09:00 lit-18: 00 off) and illumination conditions of 150-300 Lux, The animals were divided into groups in which the average body weight was matched. Animals were orally administered at a dose of 20 ml / kg once a day for 14 days, and the change in general condition, poisoning symptom , Mobility, appearance, autonomic nervous system, weight change, and presence of dead animals.
실험 결과에 의하면, 실험기간 동안 체중에 있어서 5% 이내의 변화를 보였으나 유의성은 없었고, 시료의 양을 시험동물에 투여가능한 최대량인 kg당 20ml의 최고 농도를 선정하였음에도 사망동물이 관찰되지 않아 개략의 치사량 산출은 불가하였으므로 LD50은 20ml/kg B.W. 이상인 것으로 나타났고, 특이한 일반증상이나 부검시 특이한 병변이 관찰되지 않았으므로 이를 종합적으로 판단해보면 상기 조성물은 독성이 없는 것으로 판명되었다.
According to the experimental results, there was no significant difference in the body weight during the experimental period, but there was no significant difference. The highest concentration of 20 ml per kg, which is the maximum amount of sample to be administered to the test animal, was selected, LD 50 was more than 20 ml / kg BW because of the inability to calculate the lethal dose, and it was found that the composition was not toxic when it was judged according to the general symptoms or the specific lesion upon autopsy.
실시예Example 9: 혈액 9: blood 클롯Clout 분해 분석 Decomposition analysis
혈액을 공급받아 미리 질량을 측정해놓은 여러 개의 튜브에 각각 0.5 ml씩 담고 37℃에서 45분 동안 반응시켜 클롯을 형성하고, 클롯을 형성시킨 후 혈청 층을 완전히 제거하고 클롯 질량 측정하였다. 여기에 실시예 1의 황칠 추출물을 반응시켜 혈액 클롯 분해효과를 확인하였다.0.5 ml of each of the tubes was subjected to 45 minutes of reaction at 37 ° C to form clots. After the clots were formed, the serum layer was completely removed and the clot mass was measured. Here, the extract of Huangchil of Example 1 was reacted to confirm the blood clot decomposing effect.
그 결과를 도 1에 나타내었다. 도 1은 황칠 추출물의 마우스 혈액 클롯 분해 분석의 결과도이다. 대조군은 인산염 완충액만을 포함한 것이고, 황칠 추출물은 100 μg을 포함하였다.The results are shown in Fig. FIG. 1 is a result of analysis of mouse blood clot analysis of Huangchil extract. FIG. The control group contained only phosphate buffer and the Huangchil extract contained 100 μg.
마우스 혈액 클롯 분해 분석에서 황칠 추출물 100 μg이 피브린 클롯을 약 65 % 분해시켰다. 마우스 혈액 클롯을 이용한 in vitro 실험결과를 통해 황칠 추출물의 마우스의 혈액에서 형성된 클롯을 직접적으로 분해할 수 있는 혈전분해활성을 확인할 수 있었다.
In mouse blood clot lysis analysis, 100 μg of Huangchil extract degraded the fibrin clone by about 65%. Mouse blood clot Used in The results of the in vitro experiments confirmed the thrombolytic activity of Huangchil extract which can directly decompose clots formed in the blood of mouse.
실시예Example 10: 지질분해 효과 10: Lipid degradation effect
(1) TBA 플레이트 에세이(1) TBA plate assay
실시예 1의 황칠 추출물 10 μl을 트리부티린 0.1 ml 및 아가 0.1 g을 포함하는 TBA(tributyrin agar) 플레이트에 3mm 환을 만들어 침적시킨 후 37 ℃에서 12 시간 동안 반응시켰다. 반응시킨 후 황칠추출물이 분해시킨 clear zone을 확인하였다.Ten .mu.l of the Huangchil extract of Example 1 was immersed in a 3 mm ring on a TBA (tributyrin agar) plate containing 0.1 ml of tributyrin and 0.1 g of agar, followed by reaction at 37.degree. C. for 12 hours. After the reaction, the clear zone, which was decomposed by Huangchil extract, was identified.
황칠 추출물의 TBA(tributyrin agar) 플레이트 에세이를 수행한 결과를 도 2에 나타내었다. 도 2는 황칠 추출물의 TBA 플레이트 에세이의 결과도이다. Buffer는 인산염 완충액만을 함유한 것이고, 황칠 추출물은 10 μg을 포함하였다. 위 결과로 부터 황칠 추출물 10 μg은 지질을 분해시켜 환 주위에 clean zone을 확인할 수 있었다. 이 실험을 통해 yellow lacquer extract가 지질 성분을 직접적으로 분해하는 효과를 확인하였다.
The results of TBA (tributyrin agar) plate assay of Huangchil extract are shown in Fig. 2 is a result of TBA plate assay of Huangchil extract. Buffer contained only phosphate buffer, and Huangchil extract contained 10 μg. From the above results, 10 μg of Huangchil extract was able to decompose lipid and identify a clean zone around the ring. This experiment confirmed that yellow lacquer extract directly decomposes lipid components.
(2) 지질분해효소 합성기질을 이용한 지질 분해 활성 에세이(2) Lipid degradation activity assay using lipidase synthesis substrate
효소 활성측정은 4-nirtophenyl palmitate, 4-nitrophenyl butryrate를 사용한 colorimetric 방법(Stuer et al., 1986)에 의하여 수행되었다. 실시예 1의 황칠 추출물 1 mg을 1 ml의 50 mM 인산염 완충액(pH 6.0)에 녹이고 10 μl의 기질 ㅇ요용액(100 mM p-nitrophenyl butyrate (pNPB) diluted in 2-propanol)을 첨가한 후 10분 동안 30 ℃에서 반응시켰다. 2000 g로 4 ℃ 조건에서 5분간 원심분리 후 상층액을 회수하여 활성을 측정하였다. 지질분해효소 활성은 생성된 p-nitrophenol의 양을 410 nm에서 측정하였다. 효소 1 unit의 정의는 1분당 1 μM의 p-nitrophenol을 생산하는 효소의 양을 나타낸다. 그 결과를 다음의 표 1에 나타내었다.Enzyme activity was measured by a colorimetric method (Stuer et al., 1986) using 4-nitrophenyl palmitate and 4-nitrophenyl butryrate. 1 mg of Huangchil extract of Example 1 was dissolved in 1 ml of 50 mM phosphate buffer solution (pH 6.0), and 10 μl of diluted in 2-propanol (100 mM p-nitrophenyl butyrate (pNPB) Lt; 0 > C for 30 minutes. The supernatant was recovered after 2000 g of centrifugation at 4 ° C for 5 minutes and the activity was measured. Lipolytic enzyme activity was measured at 410 nm in the amount of p-nitrophenol produced. The definition of one unit of enzyme is the amount of enzyme that produces 1 μM p-nitrophenol per minute. The results are shown in Table 1 below.
상기 표 1의 결과로부터 확인할 수 있는 바와 같이 황칠 추출물 1 mg이 각 기질을 사용하여 p-nitrophenyl butyrate 기질에서는 6860 mU/ml, p-nitrophynyl palmitate 기질에서는 990 mU/ml의 지질 ㅂ부분lyㅎ해 활성을 이 실험을 통해 황칠 추출물이 지질 성분을 직접적으로 분해하는 효소인 리파아제와 같은 활성을 확인하였으며 각 기질에서 높은 활성을 확인하였다.
As can be seen from the results in Table 1, 1 mg of Huangchil extract was 6860 mU / ml in the p- nitrophenyl butyrate substrate and 990 mU / ml in the p- nitropyryl palmitate substrate using each substrate, In this experiment, the activity of lipase, which is an enzyme that directly decomposes lipid components, was confirmed and high activity was confirmed in each substrate.
(3) 효소 분석(3) Enzyme analysis
4-nirtophenyl palmitate, 4-nitrophenyl butryrate 의 substrates를 이용하였고 Hanes-Woolf plot 과 Woolf-Augustinsson-hofstee plot을 이용하여 Vmax (mU/min/ml), Km (μM), Kcat (s-1), Kcat/Km (μM-1 s-1)을 산출하였다. 황칠 추출물 100 μg을 100 μl의 50 mM phosphate buffer (pH 6.0) 에 녹이고 1 μl 의 substrate solution (10 mM p-nitrophenyl butyrate (pNPB) diluted in 2-propanol)을 첨가한 후 10분 동안 410 nm에서 측정하고 그 결과를 아래의 표 2에 나타내었다.4-nirtophenyl palmitate, 4-nitrophenyl substrates were used for the Hanes-Woolf plot and Woolf-butryrate Augustinsson-hofstee plot of V max (mU / min / ml ), K m (μM), K cat (s -1 using ), And K cat / K m (μM -1 s -1 ). 100 μg of Huangchil extract was dissolved in 100 μl of 50 mM phosphate buffer (pH 6.0), and 1 μl of substrate solution (diluted in 2-propanol with 10 mM p-nitrophenyl butyrate (pNPB) And the results are shown in Table 2 below.
(mU/min/ml)V max
(mU / min / ml)
(μM)K m
(μM)
(s-1)K cat
(s -1 )
운동 변수는 Hanes-Woolf plot and Woolf-Augustinsson-hofstee plot analyses에 의해 얻었다. Km 및 Vmax는 각각 plot x and y intercepts로 부터 계산하였다. 촉매 속도 상수(Kcat)는 식 Vmax/[Eo]로 부터 유도하였다.The kinetic parameters were obtained by Hanes-Woolf plot and Woolf-Augustinsson-hofstee plot analyses. Km and Vmax are calculated from plot x and y intercepts, respectively. The catalyst rate constant (Kcat) was derived from the equation V max / [Eo].
상기 표 2의 결과로 부터 확인할 수 있는 바와 같이, 황칠 추출물(100 μg)은 각 기질에서 Vmax, Km , Kcat , Kcat/Km 값을 확인하였으며 그 수치는 각 기질에서 p-nitrophenyl butyrate (6860 mU/min/ml, 1580 μM, 171.5 s-1, 0.1085 μM-1s-1), p-nitrophynyl palmitate (990 mU/min/ml, 3880 μM, 24.75 s-1, 0.0064 μM-1s-1) 의 enzymatic activity를 보였다.
As can be seen from the results of Table 2 above, the extract of Huangchil (100 μg) showed V max , K m , K cat , and K cat / K m The results were as follows: p- nitrophenyl butyrate (960 mU / min / ml, 1580 μM, 171.5 s -1 , 0.1085 μM -1 s -1 ) and p- nitrophenyl palmitate , 3880 μM, 24.75 s -1 , and 0.0064 μM -1 s -1 ), respectively.
실시예Example 11: 항고지혈효과 시험 11: Antihyperlipidemic effect test
실험동물 랫트의 꼬리 정맥을 통해 채혈하고, 채혈된 혈액은 실온에서 30분 정도 방치 후, 3000 rpm으로 20분 동안 원심분리하여 혈청을 추출하고 이를 분석 시까지 -30℃에 보관하였다. Total cholesterol (총 콜레스테롤), TG (중성지방), HDL-C (고밀도지단백 콜레스테롤), LDL-C (저밀도지단백 콜레스테롤), VLDL-C(초저밀도지단백 콜레스테롤)를 측정하여 항고지혈증 효과를 분석하고 Friedewald 식을 이용한 농도계산법으로 분석하였다. Blood was collected from the rat via the tail vein. The blood was left at room temperature for 30 minutes, centrifuged at 3000 rpm for 20 minutes, and the serum was extracted and stored at -30 ° C until analysis. We analyzed the effects of total cholesterol, TG, HDL-C, LDL-C and VLDL-C in hypercholesterolemic patients. Friedewald Were analyzed by the concentration calculation method.
고지혈증을 유발시킨 랫트에 황칠추출물 원료를 첨가한 사료를 식이시켜 항고지혈증 효과를 분석한 결과를 도 3에 나타내었다. 도 3은 고지혈증 유발 쥐에서 황칠 추출물의 항고지혈 효과를 나타내는 그라프도이다. C는 대조군으로서, 정상 랫트의 혈장이고, NC는 음성 대조군으로서 고지혈증 유발 쥐의 혈장이며, 샘플은 실험군으로서 황칠 추출물 (1 mg)을 공급한 고지혈증 유발한 랫트의 혈장이다.The results of analyzing the effect of anti-hyperlipemia by feeding diets supplemented with Huangchil extract material to hyperlipidemic rats are shown in Fig. FIG. 3 is a graph showing the antihyperlipidemic effect of Huangchil extract in hyperlipemia-induced rats. C is the plasma of normal rats as a control, NC is the plasma of hyperlipemia-induced rats as a negative control, and the sample is the plasma of hyperlipemia-induced rats fed with Huangchil extract (1 mg) as an experimental group.
도 3의 결과로부터 확인할 수 있는 바와 같이, 일반사료만 식이시킨 control group (N, 일반식이)의 총콜레스테롤(total cholesterol) 수치는 107 mg/dL, HDL-cholesterol (고밀도 지단백 콜레스테롤) 수치는 74.9 mg/dL, LDL-cholesterol (저밀도 지단백 콜레스테롤) 수치는 10.7 mg/dL, VLDL-cholesterol (초저밀도 지단백 콜레스테롤) 수치는 21.4 mg/dL, TG (중성지방) 수치는 106.9 mg/dL로 측정되었다.As shown in FIG. 3, the total cholesterol level and HDL-cholesterol level of the control group (N, general diet) fed with only normal diet were 107 mg / dL and 74.9 mg / LDL-cholesterol, LDL-cholesterol and LDL-cholesterol were 10.7 mg / dL and 21.4 mg / dL, respectively, and 106.9 mg / dL, respectively.
High-cholesterol 사료만 식이시킨 negative control group (NC, 고지혈증 유발 그룹)의 총콜레스테롤 수치는 130.4 mg/dL, HDL수치는 68.9 mg/dL, LDL수치는 34 mg/dL, VLDL수치는 27.5 mg/dL, TG (중성지방) 수치는 118.9 mg/dL로 측정되었다. 이에 일반사료만 식이시킨 Normal group의 총콜레스테롤, HDL, LDL, VLDL, TG를 비교한 결과, 총콜레스테롤은 약 21.9 % 증가하였고 HDL은 약 8 % 감소하였다. 또한, LDL은 약 317.8 배 증가하였고 VLDL와 TG는 25 %, 18 % 증가하였다. The total cholesterol, LDL, and VLDL values of the negative control group (NC, hyperlipidemia-inducing group) fed with high-cholesterol diet were 130.4 mg / dL, 68.9 mg / dL and 27.5 mg / dL, , And TG (triglyceride) levels were measured as 118.9 mg / dL. The total cholesterol, HDL, LDL, VLDL, and TG of normal group fed normal diet were increased by 21.9% and 8%, respectively. LDL increased about 317.8 times and VLDL and TG increased 25% and 18%, respectively.
고지혈증이 유발된 랫트에 황칠추출물 원료를 첨가한 사료를 식이 시킨 sample group의 결과에서 총콜레스테롤수치는 113.3 mg/dL, HDL수치는 70.3 mg/dL, LDL수치는 24.2 mg/dL, VLDL수치는 18.8 mg/dL, TG수치는 93.9 mg/dL로 측정되었다. 이에 일반사료를 식이시킨 control group 및 고콜레스테롤 사료를 식이시킨 negative control group과 총콜레스테롤, HDL, LDL, VLDL, TG를 비교한 결과, 총콜레스테롤, VLDL, TG 수치는 정상수치로 회복되었고, LDL은 34 mg/dL에서 24.2 mg/dL로 다소 저하되었으며, 또한, 총콜레스테롤 및 HDL수치도 다소 저하되어 황칠추출물의 식이에 의한 회복효과를 확인할 수 있었다.The LDL and LDL values of the rats induced by hyperlipidemia were 113.3 mg / dL, 70.3 mg / dL and 24.2 mg / dL, respectively, and the VLDL values were 18.8 mg / dL, and the TG value was measured as 93.9 mg / dL. Total cholesterol, HDL, LDL, VLDL, and TG levels were restored to normal levels, and LDL, LDL, and TG levels were restored to normal levels. 34 mg / dL and 24.2 mg / dL, respectively, and total cholesterol and HDL levels were slightly lowered.
또한, AI(동맥경화 지수, Atherogenic index, (총콜레스테롤 - HDL-콜레스테롤)/HDL-콜레스테롤), HDL/LDL ratio, TC/HDL ratio을 산출하여 비교분석하고 그 결과를 표 3에 나타내었다.In addition, AI (atherogenic index, (total cholesterol-HDL-cholesterol) / HDL-cholesterol), HDL / LDL ratio and TC / HDL ratio were calculated and compared and the results are shown in Table 3.
결과적으로 고지혈증을 유발시킨 랫트에 황칠추출물 원료를 첨가한 사료를 14일 동안 식이시킨 결과, 5 가지 모든 항목의 결과에서 혈행개선 효과(고지혈증 예방효과)를 갖고 있음을 확인하였으며, 동맥경화지수, Total cholesterol/HDL ratio와 HDL/LDL ratio의 수치에서도 항고지혈 효과의 유의성을 확인하였다.
As a result, it was confirmed that rats that induced hyperlipemia had a blood circulation improving effect (hyperlipemia prevention effect) in the results of all 5 items after feeding diets supplemented with Huangchil extract material for 14 days, cholesterol / HDL ratio and HDL / LDL ratio.
현재, 국내의 경우도 농촌 노동력이 감소하는 경향을 보이고 있고 휴경하는 논이 늘고 있는데 위와 같은 효능을 갖는 황칠 수액 등을 이용한 제품 다양화 기술을 연구하여 천연자원을 이용한 부가가치 산업을 육성하면, 농가 소득의 향상은 물론 농수산물 수입 개방에 따른 국제 경쟁력 제고에도 일조할 수 있을 것으로 판단된다.At present, the domestic labor force shows a tendency to decrease and the number of paddy fields is increasing. By cultivating the product diversification technology using the above-mentioned efflorescent yellow liquor, etc. and fostering the value added industry using natural resources, And to enhance international competitiveness through the opening of agricultural and marine products imports.
또한, 우리 고유의 천연물질인 황칠의 기능성에 대한 많은 연구가 이루어져 황칠이 목재, 섬유, 화장품, 약품 등 다양한 재료에 응용될 수 있는 신기능성물질로서 개발된다면 농가소득증대에 일익을 담당할 수 있는 훌륭한 유망 작목으로서 기능할 수 있을 것으로 판단된다.In addition, many studies on the function of Huangchil, which is our natural material, have been made so that if Huangchil is developed as a new functional material applicable to various materials such as wood, fiber, cosmetics and medicine, It will be able to function as a promising artwork.
위와 같은 결과로부터 항고지혈 효과 검증가 검증됨으로써 건강지향성 식품에 응용 가능할 뿐만 아니라 개발된 황칠 추출물의 소재를 이용하여 사회적 문제로 대두되고 있는 고령화 시대로 접어든 60대 이후의 노년층을 위한 맞춤형 건강지향성 실버푸드 제품 개발하고, 퇴행성 신체기능의 예방, 억제 등의 건강한 삶을 유지하기 위한 제품으로 활용하고, 노인성 질환의 예방을 목적으로 하는 부작용 없이 지속적으로 섭취할 수 있는 예방 중심의 헬쓰케어 산업에도 활용 가능하다.As a result of the above results, it was confirmed that the anti-hyperlipidemic effect was verified, so that it could be applied not only to health-oriented foods but also to the customized health-oriented silver food for the elderly people in their 60s or older, It can also be used in a preventive centered healthcare industry that can be used as a product to maintain a healthy life such as prevention and suppression of degenerative physical function, and can be continuously consumed without side effects for the prevention of geriatric diseases .
뿐만 아니라 지역 참여기업에 의한 노인 복합 질환 맞춤형 기능성 식품 소재의 대량생산기술 개발에 의한 지역소득원 및 생물산업에 대한 전문인력의 고용 창출 효과가 있다.In addition, it has the effect of creating employment of local labor sources and biotechnology industry by mass production technology of functional food ingredients tailored for the elderly by local participating companies.
Claims (3)
황칠나무를 세척한 후, 60~90% 메탄올에 침지시킨 후 3일 내지 15일 동안 실온에서 방치한 후 추출액만 분리하고, 얻은 추출액을 증발하여 농축시킨 후 동결건조하여 분말상태로 제조하거나,
채취한 황칠나무를 깨끗이 세척하고 건조하여 세절한 후, 에탄올 60~90%에 침지시킨 후, 실온에서 1~3 주 동안 방치한 후 추출액을 분리하고, 얻은 추출액을 증발하여 농축시킨 후 동결건조하여 분말상태로 제조하거나, 또는
황칠나무를 깨끗이 세척하여 건조하여 세절한 다음 이를 용기에 넣고 황칠나무와 물을 중량을 기준으로 1:1~5중량부로 혼합하여 고압멸균솥에 넣고 95 ~ 125℃의 온도에서 2 ~ 5 시간 동안 추출하여 여과하여 농축하여 얻어진 것을 특징으로 하는 식품 조성물.2. The method according to claim 1,
After washing the woodwort, it is immersed in 60 to 90% methanol, and then left at room temperature for 3 to 15 days. Only the extract is separated, and the obtained extract is evaporated to concentrate and freeze-
The extracts were separated by evaporation, and the extracts were evaporated to dryness, and the extracts were lyophilized. After drying, the extracts were washed three times and then immersed in 60 to 90% ethanol. Or in powder form, or
It is mixed with 1: 1 ~ 5 parts by weight of Hwangjak tree and water, put into a high pressure autoclave and heated at 95 ~ 125 ℃ for 2 ~ 5 hours Extracting, filtering and concentrating the food composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140002226A KR101644183B1 (en) | 2014-01-08 | 2014-01-08 | Food composition for preventing senile dimentia comprising Dendropanax morbifera Lev. extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140002226A KR101644183B1 (en) | 2014-01-08 | 2014-01-08 | Food composition for preventing senile dimentia comprising Dendropanax morbifera Lev. extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150082811A true KR20150082811A (en) | 2015-07-16 |
KR101644183B1 KR101644183B1 (en) | 2016-07-29 |
Family
ID=53884726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020140002226A KR101644183B1 (en) | 2014-01-08 | 2014-01-08 | Food composition for preventing senile dimentia comprising Dendropanax morbifera Lev. extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101644183B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220026474A (en) * | 2020-08-25 | 2022-03-04 | 윤경식 | The manufacturing method of the feed for obtaining the egg or the meat |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200064204A (en) | 2018-11-28 | 2020-06-08 | 농업회사법인 휴림황칠(주) | Composition for improving atopic dermatitis containing Dendropanax morbifera Lev. extract |
KR102165106B1 (en) * | 2019-04-05 | 2020-10-14 | 정혜린 | A pill or granule comprising Dendropanax Morbifera extract for improving constipation disease and a method for producing the same. |
KR20230075955A (en) | 2021-11-23 | 2023-05-31 | 경성대학교 산학협력단 | Parmaceutical composition comprising extract of Dendropanax morbiferus including chlorogenic acid with enhanced bioavailability as an effective componinet and preparation method thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000004499A (en) * | 1998-06-30 | 2000-01-25 | 박호군 | Dendropanax morbifera lev extract having anti-cancer activity |
KR20030075999A (en) | 2002-03-22 | 2003-09-26 | 주식회사 디피바이오텍 | Dendropanax morbifera Lev. extract, fraction and pharmaceutical composition containing thereof for recovering and proliferating effects on tibial tissue and periodontium ligamental tissue |
KR20030079205A (en) * | 2002-04-02 | 2003-10-10 | 주식회사 디피바이오텍 | Dendropanax morbifera Lev. extract having a protective effect of hepatic cells, Dendropanax morbifera Lev. fractions, and pharmaceutical composition containing the same |
KR20110067789A (en) * | 2009-12-15 | 2011-06-22 | 한국인스팜(주) | A composition comprising the extract of crude drug selected from eriobotryae folium and dendropanax morbiferafor treating and preventing neuro-degenerative disease |
KR20130059128A (en) * | 2011-11-28 | 2013-06-05 | 이종수 | MATERIAL AS AGONIST FOR PPARα, PPARγ AND PPARδ USING DENDROPANAX MORBIFERA LEV. LEAF AND THE EXTRACTING METHOD THEREOF |
-
2014
- 2014-01-08 KR KR1020140002226A patent/KR101644183B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000004499A (en) * | 1998-06-30 | 2000-01-25 | 박호군 | Dendropanax morbifera lev extract having anti-cancer activity |
KR20030075999A (en) | 2002-03-22 | 2003-09-26 | 주식회사 디피바이오텍 | Dendropanax morbifera Lev. extract, fraction and pharmaceutical composition containing thereof for recovering and proliferating effects on tibial tissue and periodontium ligamental tissue |
KR20030079205A (en) * | 2002-04-02 | 2003-10-10 | 주식회사 디피바이오텍 | Dendropanax morbifera Lev. extract having a protective effect of hepatic cells, Dendropanax morbifera Lev. fractions, and pharmaceutical composition containing the same |
KR20110067789A (en) * | 2009-12-15 | 2011-06-22 | 한국인스팜(주) | A composition comprising the extract of crude drug selected from eriobotryae folium and dendropanax morbiferafor treating and preventing neuro-degenerative disease |
KR20130059128A (en) * | 2011-11-28 | 2013-06-05 | 이종수 | MATERIAL AS AGONIST FOR PPARα, PPARγ AND PPARδ USING DENDROPANAX MORBIFERA LEV. LEAF AND THE EXTRACTING METHOD THEREOF |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220026474A (en) * | 2020-08-25 | 2022-03-04 | 윤경식 | The manufacturing method of the feed for obtaining the egg or the meat |
Also Published As
Publication number | Publication date |
---|---|
KR101644183B1 (en) | 2016-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Prakash et al. | Acerola, an untapped functional superfruit: a review on latest frontiers | |
KR102056108B1 (en) | Composition for removing hangover and improving liver function | |
US20120058134A1 (en) | Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant | |
KR101697146B1 (en) | A high efficient method for extracting silymarin from cirsium pendulum | |
US6991811B1 (en) | Echinacea induction of phase II enzymes | |
KR101644183B1 (en) | Food composition for preventing senile dimentia comprising Dendropanax morbifera Lev. extract | |
Sulieman et al. | Physicochemical characteristics of local varieties of tamarind (Tamarindus indica L), Sudan | |
EP2022503B1 (en) | Encapsulated vaccine extracts with balanced intestinal release | |
CN105072913B (en) | Fruit cell and the method with such cell therapy disease is mass produced | |
JP6778026B2 (en) | Whitening agents and whitening foods and drinks containing 4'-demethylnobiletin as an active ingredient | |
KR102507651B1 (en) | Fermented Stauntonia hexaphylla for hangover relief, alcoholic liver disease or liver function improvement using fermented enzyme complex solution containing traditional brewery yeast and its manufacturing method | |
Patel et al. | In vitro shoot multiplication from nodal explants of Coccinia grandis (L.) Voigt. and it’s antidiabetic and antioxidant activity | |
WO2007007994A1 (en) | Food composition for improving liver function comprising a lonicera caerulea l. var. edulis extract | |
KR20170015618A (en) | Functional alcoholic liquors using cordyceps mushroomand method of producing the same | |
KR20230138679A (en) | Composition for preventing or improving recognitive function disorder or memory disorder comprising fermented rhodiola sachalinesis | |
Karim et al. | Hypoglycemic and antidyslipidemic potential of Pleurotus ostreatus in streptozotocin-induced diabetic rats | |
KR20150101558A (en) | Anti-obesity health functional fermented soybean beverage having flavored taste | |
CN104584821B (en) | A kind of cultivation of plants method and application containing rhodioside | |
Patra et al. | Nutritional and antinutritional properties of Carissa carandas and Cordia dichotoma, two medicinally important wild edible fruits of Odisha | |
US8287927B2 (en) | Processed product of fenugreek seeds and method for producing the same | |
KR20100071781A (en) | Preparing method of cactus powder, fuctional food using the same cactus powder and preparing method thereof | |
KR20160095738A (en) | Functional food comprising Dendropanax morbifera Lev. fermentation vinegar and process for preparing the same | |
KR101743710B1 (en) | Food composition containing heat-treated solar sea salt for preventing hangover and method for manufacturing the same | |
KR101693752B1 (en) | Fermented bellflower root candy and method for preparation thereof | |
Ishwah et al. | Nutritional and Phytochemical Screening of Raw and Boiled Hypocotyls of African Fan Palm (Borassus aethiopum) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E90F | Notification of reason for final refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
E801 | Decision on dismissal of amendment | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20190701 Year of fee payment: 4 |